{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=INCMGA00012.&page=2", "query": { "intervention": "INCMGA00012.", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=INCMGA00012.&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-25T21:44:16.922Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03522142", "title": "A Study Exploring the Safety and Tolerability of INCB081776 in Participants With Advanced Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors" ], "interventions": [ { "name": "INCB081776", "type": "DRUG" }, { "name": "INCMGA00012", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 83, "start_date": "2018-08-27", "completion_date": "2025-09-10", "has_results": false, "last_update_posted_date": "2025-10-09", "last_synced_at": "2026-09-25T21:44:16.922Z", "location_count": 9, "location_summary": "New Haven, Connecticut • Boston, Massachusetts • Hackensack, New Jersey + 6 more", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "New York", "state": "New York" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03522142" }, { "nct_id": "NCT05743595", "title": "Neoantigen-based Personalized DNA Vaccine With Retifanlimab PD-1 Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Unmethylated Glioblastoma" ], "interventions": [ { "name": "Personalized Neoantigen DNA vaccine", "type": "BIOLOGICAL" }, { "name": "Retifanlimab", "type": "BIOLOGICAL" }, { "name": "TDS-IM v 2.0 electroporation device", "type": "DEVICE" } ], "intervention_types": [ "BIOLOGICAL", "DEVICE" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 27, "start_date": "2023-10-27", "completion_date": "2029-03-09", "has_results": false, "last_update_posted_date": "2026-05-04", "last_synced_at": "2026-09-25T21:44:16.922Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT05743595" }, { "nct_id": "NCT03406949", "title": "MGD009/MGA012 Combination in Relapsed/Refractory Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors" ], "interventions": [ { "name": "obrindatamab", "type": "BIOLOGICAL" }, { "name": "retifanlimab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "MacroGenics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2018-02-27", "completion_date": "2022-04-27", "has_results": false, "last_update_posted_date": "2022-05-19", "last_synced_at": "2026-09-25T21:44:16.922Z", "location_count": 10, "location_summary": "Duarte, California • Los Angeles, California • Newport Beach, California + 6 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03406949" }, { "nct_id": "NCT06056895", "title": "Triple Immune Checkpoint Inhibition for Advanced or Metastatic PD-(L)1 Refractory Merkel Cell Carcinoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Unresectable Clinical Stage III Merkel Cell Carcinoma AJCC v8", "Clinical Stage IV Merkel Cell Carcinoma AJCC v8", "Merkel Cell Carcinoma" ], "interventions": [ { "name": "Biopsy", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Retifanlimab", "type": "BIOLOGICAL" }, { "name": "Tuparstobart", "type": "DRUG" }, { "name": "Verzistobart", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL", "DRUG" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2023-11-08", "completion_date": "2027-04-30", "has_results": false, "last_update_posted_date": "2026-08-06", "last_synced_at": "2026-09-25T21:44:16.922Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT06056895" }, { "nct_id": "NCT05083754", "title": "Carmustine Wafer in Combination With Retifanlimab and Radiation With/Without Temozolomide in Subjects With Glioblastoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Glioblastoma Multiforme" ], "interventions": [ { "name": "Retifanlimab", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Radiation Therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 50, "start_date": "2022-08-31", "completion_date": "2029-01", "has_results": false, "last_update_posted_date": "2026-01-09", "last_synced_at": "2026-09-25T21:44:16.922Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT05083754" }, { "nct_id": "NCT07765836", "title": "Vilastobart+Retifanlimab in BRCA or PALB2 Deficient PC", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pancreatic Cancer Metastatic" ], "interventions": [ { "name": "vilastobart (XTX101)", "type": "DRUG" }, { "name": "Retifanlimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2027-01", "completion_date": "2030-12-31", "has_results": false, "last_update_posted_date": "2026-08-14", "last_synced_at": "2026-09-25T21:44:16.922Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT07765836" }, { "nct_id": "NCT02393248", "title": "Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Lung Cancer", "Solid Tumor", "Gastric Cancer", "Urothelial Cancer", "Endometrial Cancer", "Multiple Myeloma", "Myeloproliferative Neoplasms", "Breast Cancer", "Cholangiocarcinoma", "UC", "MPN" ], "interventions": [ { "name": "Pemigatinib", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" }, { "name": "Retifanlimab", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 201, "start_date": "2015-02-27", "completion_date": "2021-12-17", "has_results": true, "last_update_posted_date": "2023-01-06", "last_synced_at": "2026-09-25T21:44:16.922Z", "location_count": 19, "location_summary": "Birmingham, Alabama • West Hollywood, California • New Haven, Connecticut + 16 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "West Hollywood", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Port Saint Lucie", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02393248" }, { "nct_id": "NCT03679767", "title": "A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Non-small Cell Lung Cancer", "Locally Advanced Urothelial Cancer", "Metastatic Urothelial Cancer", "Unresectable Melanoma", "Metastatic Melanoma", "Locally Advanced Renal Cell Carcinoma", "Metastatic Clear-Cell Renal Cell Carcinoma" ], "interventions": [ { "name": "Retifanlimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 121, "start_date": "2019-01-09", "completion_date": "2022-06-28", "has_results": true, "last_update_posted_date": "2023-07-21", "last_synced_at": "2026-09-25T21:44:16.922Z", "location_count": 18, "location_summary": "Fresno, California • San Marcos, California • Santa Rosa, California + 13 more", "locations": [ { "city": "Fresno", "state": "California" }, { "city": "Fresno", "state": "California" }, { "city": "San Marcos", "state": "California" }, { "city": "Santa Rosa", "state": "California" }, { "city": "Santa Rosa", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03679767" }, { "nct_id": "NCT06160206", "title": "Retifanlimab with Bevacizumab and Hypofractionated Radiotherapy for the Treatment of Recurrent Glioblastoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Glioblastoma", "Recurrent WHO Grade 4 Glioma" ], "interventions": [ { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Electronic Health Record Review", "type": "OTHER" }, { "name": "Hypofractionated Radiation Therapy", "type": "RADIATION" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Retifanlimab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE", "OTHER", "RADIATION" ], "sponsor": "Academic and Community Cancer Research United", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 134, "start_date": "2024-10-02", "completion_date": "2030-11-30", "has_results": false, "last_update_posted_date": "2024-11-19", "last_synced_at": "2026-09-25T21:44:16.922Z", "location_count": 3, "location_summary": "Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT06160206" }, { "nct_id": "NCT04387084", "title": "Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Malignant Skin Neoplasm", "Metastatic Malignant Skin Neoplasm" ], "interventions": [ { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Avelumab", "type": "DRUG" }, { "name": "Cemiplimab", "type": "BIOLOGICAL" }, { "name": "Durvalumab", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Short-Term Fasting", "type": "OTHER" }, { "name": "Dostarlimab", "type": "BIOLOGICAL" }, { "name": "Retifanlimab", "type": "BIOLOGICAL" }, { "name": "Toripalimab", "type": "BIOLOGICAL" }, { "name": "Tislelizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "University of Southern California", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2020-08-12", "completion_date": "2028-03-31", "has_results": false, "last_update_posted_date": "2026-09-21", "last_synced_at": "2026-09-25T21:44:16.922Z", "location_count": 2, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04387084" } ] }